| Literature DB >> 27491546 |
Huimin Wang1, Yan Yang1, Lin Lin2, Wenlong Zhou3, Minzhi Liu3, Kedi Cheng3, Wei Wang4.
Abstract
BACKGROUND: Glycosylation of flavonoids is a promising approach to improve the pharmacokinetic properties and biological activities of flavonoids. Recently, many efforts such as enzymatic biocatalysis and the engineered Escherichia coli biotransformation have increased the production of flavonoid glucosides. However, the low yield of flavonoid glucosides can not meet the increasing demand for human medical and dietary needs. Saccharomyces cerevisiae is a generally regarded as safe (GRAS) organism that has several attractive characteristics as a metabolic engineering platform for the production of flavonoid glucosides. However, endogenous glucosidases of S. cerevisiae as a whole-cell biocatalyst reversibly hydrolyse the glucosidic bond and hinder the biosynthesis of the desired products. In this study, a model flavonoid, scutellarein, was used to exploit how to enhance the production of flavonoid glucosides in the engineered S. cerevisiae.Entities:
Keywords: Glucosidase; Glucosyltransferase; Saccharomyces cerevisiae; Scutellarein 7-O-glucoside
Mesh:
Substances:
Year: 2016 PMID: 27491546 PMCID: PMC4973555 DOI: 10.1186/s12934-016-0535-2
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Fig. 1Determination of the kinetic parameters for SbGTs. The apparent K m values were detected using scutellarein as an acceptor and UDP-Glu as a donor at 30 °C and a pH of 7.5. The apparent K m values of SbGT30 (a), SbGT34 (b) and SbGT56 (c) were 188, 121 and 222 μM, respectively
Fig. 2Hydrolytic activity to luteolin 7-O-glucoside in strains with the deletion of glucosidases. a Biomass (OD600). b The remaining rate of luteolin 7-O-glucoside in the liquid medium. The values are presented as the means, and the error bars show the SD (n = 3)
Fig. 3Differences in the level of scutellarein 7-O-glucoside produced by strains W303-1b/SbGT34, W303-1b/ES∆/SbGT34 and W303-1b/ES∆/PU/SbGT34 over time. Strains were incubated with 0.2 mM scutellarein. The values are presented as the means, and the error bars show the SD (n = 3)
Fig. 4HPLC analysis for scutellarein 7-O-glucoside from the whole-cell biocatalyst assay using strain W303-1b/ES∆/PU/SbGT34. a HPLC profile for standard scutellarein. b HPLC profile for the biocatalysis system. c HPLC profile for standard scutellarein 7-O-glucoside
Fig. 5The influence of different concentrations of scutellarein on the cell growth and the conversion rate of scutellarein to scutellarein 7-O-glucoside. The concentrations of scutellarein were 0.2, 0.4, 0.6, 0.8 and 1.0 mM. a The conversion rate of scutellarein at different concentrations over time. b Biomass (OD600). The values are presented as the means, and the error bars show the SD (n = 3)
Fig. 6The influence of different concentrations of glucose and pH conditions on the fermentation. a A comparison of the conversion rate using 0.6 mM scutellarein in four different concentrations of glucose. b A comparison of the conversion rate using 0.6 mM scutellarein in four different pH conditions. CK represents the conversion rate in the unregulated medium, and the glucose concentration was 10 %. The values are presented as the means, and the error bars show the SD (n = 3)
Fig. 7The scaled-up production of scutellarein 7-O-glucoside in the 10-L fermenter. Large-scale bioconversion in the fermenter using the SC medium supplemented with 10 % glucose. Scutellarein at concentrations of 1 and 2 mM were supplied in the reaction system at 0 and 12 h
Strains and plasmids used in this study
| Strains or plasmids | Relevant properties | Source or reference |
|---|---|---|
| Strains | ||
| | F−
| Our lab |
| | F−
| Our lab |
| |
| Our lab |
| W303-1b/EXG1∆ | W303-1b derivative with pEZ-EXG36-Trp1, EXG1∆::Trp1 | This study |
| W303-1b/SPR1∆ | W303-1b derivative with pEZ-SPR36-ADE2, SPR1∆::Ade2 | This study |
| W303-1b/YIR007W∆ | W303-1b derivative with pEZ-YIR36-Ura3, YIR007W∆::Ura3 | This study |
| W303-1b/ES∆ | W303-1b derivative with pEZ-EXG36-Trp1 and pEZ-SPR36-ADE2, EXG1∆::Trp1, SPR1∆::Ade2 | This study |
| W303-1b/SbGT34 | W303-1b derivative with pδGAPg-SbGT34 | This study |
| W303-1b/ES∆/SbGT34 | W303-1b/ES∆ derivative with pδGAPg-SbGT34 | This study |
| W303-1b/ES∆/PU/SbGT34 | W303-1b/ES∆ derivative with pδGAPg-PGM2, pδGAPh-UGP1, and pδGAPg-SbGT34 | This study |
| Plasmids | ||
| pTWIN1B | A derivative of pTWIN1, an inducible expression vector with ampicillin resistant. | Our lab |
| pTWIN1B-SbGT30 | pTWIN1B derivative with the | This study |
| pTWIN1B-SbGT34 | pTWIN1B derivative with the | This study |
| pTWIN1B-SbGT56 | pTWIN1B derivative with the | This study |
| pEZ-EXG36-TRP1 | Integration vector with Homologous fragment of | This study |
| pEZ-SPR36-ADE2 | Integration vector with Homologous fragment of | This study |
| pEZ-YIR36-URA3 | Integration vector with Homologous fragment of | This study |
| pδGAPg | pBluescript II KS(+) derivative with homologous δ region, | [ |
| pδGAPh | pBluescript II KS(+) derivative with homologous δ region, | [ |
| pδGAPg-PGM | pδGAPg derivative with | This study |
| pδGAPh-UGP1 | pδGAPh derivative with | This study |
| pδGAPg-SbGT34 | pδGAPg derivative with | This study |